Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1078-0432.CCR-14-2332 http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-14-2332 C4566854!4566854!25724518     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Cancer+Res 2015 ; 21 (11): 2471-9 Nephropedia Template TP {{tp|p=25724518|t=2015. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma |pdf=|usr=}}{{25724518}} gab.com Text Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma JO: Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=25724518 #FOAvip Purpose: The renin-angiotensin system may play a role in carcinogenesis. The purpose of this study was to evaluate the impact of angiotensin system inhibitors (ASIs) on outcomes in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era. Methods: We conducted a pooled analysis of mRCC patients treated on phase II and III clinical trials. Statistical analyses were performed using Cox regression adjusted for several risk factors and the Kaplan-Meier method. Results: 4,736 patients were included, of whom 1,487 received ASIs and 783 received other anti-hypertensive agents. Overall, ASI users demonstrated improved overall survival (OS) compared to users of other anti-hypertensive agents (adjusted HR 0.838, p=0.0105, 26.68 versus 18.07 months) and individuals receiving no anti-hypertensive therapy (adjusted HR 0.810, p=0.0026, 26.68 versus 16.72 months). When stratified by therapy type, a benefit in OS was demonstrated in ASI users compared to non-users in individuals receiving vascular endothelial growth factor targeted therapy (adjusted HR 0.737, p<0.0001, 31.12 versus 21.94 months) but not temsirolimus or interferon-alpha. An in vitro cell viability assay demonstrated that sunitinib in combination with an ASI significantly decreased RCC cell viability compared to control at physiologically relevant doses. This effect was not observed with either agent alone or with other non-ASI anti-hypertensives or temsirolimus. Conclusions: In the largest analysis to date, we demonstrate that ASI use improved survival in mRCC patients treated in the targeted therapy era. Further studies are warranted to investigate the mechanism underlying this interaction and verify our observations to inform clinical practice. Twit Text FOAVip Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma ????Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=25724518 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25724518 #FOAvip English Wikipedia <ref>{{Cite pmid|25724518}}</ref> Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma #MMPMID25724518 McKay RR; Rodriguez GE; Lin X; Kaymakcalan MD; Hamnvik OPR; Sabbisetti VS; Bhatt RS; Simantov R; Choueiri TK Clin Cancer Res 2015[Jun]; 21 (11): 2471-9 PMID25724518show ga Purpose: The renin-angiotensin system may play a role in carcinogenesis. The purpose of this study was to evaluate the impact of angiotensin system inhibitors (ASIs) on outcomes in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era. Methods: We conducted a pooled analysis of mRCC patients treated on phase II and III clinical trials. Statistical analyses were performed using Cox regression adjusted for several risk factors and the Kaplan-Meier method. Results: 4,736 patients were included, of whom 1,487 received ASIs and 783 received other anti-hypertensive agents. Overall, ASI users demonstrated improved overall survival (OS) compared to users of other anti-hypertensive agents (adjusted HR 0.838, p=0.0105, 26.68 versus 18.07 months) and individuals receiving no anti-hypertensive therapy (adjusted HR 0.810, p=0.0026, 26.68 versus 16.72 months). When stratified by therapy type, a benefit in OS was demonstrated in ASI users compared to non-users in individuals receiving vascular endothelial growth factor targeted therapy (adjusted HR 0.737, p<0.0001, 31.12 versus 21.94 months) but not temsirolimus or interferon-alpha. An in vitro cell viability assay demonstrated that sunitinib in combination with an ASI significantly decreased RCC cell viability compared to control at physiologically relevant doses. This effect was not observed with either agent alone or with other non-ASI anti-hypertensives or temsirolimus. Conclusions: In the largest analysis to date, we demonstrate that ASI use improved survival in mRCC patients treated in the targeted therapy era. Further studies are warranted to investigate the mechanism underlying this interaction and verify our observations to inform clinical practice. äAngiotensin system inhibitors and survival outcomes in patients with m(epmc).pdf DeepDyve Pubget Overpricing